Case report: Successful treatment of OXA-23 neurosurgical infection and meningitis with sulbactam-durlobactam combination therapy

Authors

Jacob W. Snowdin, Department of Infectious Diseases, Maine Medical Center, Portland, ME, United States.
Nicholas J. Mercuro, Department of Infectious Diseases, Maine Medical Center, Portland, ME, United States.
Michael P. Madaio, Department of Infectious Diseases, Maine Medical Center, Portland, ME, United States.
Stephen A. Rawlings, Department of Infectious Diseases, Maine Medical Center, Portland, ME, United States.

Document Type

Article

Publication Date

1-1-2024

Journal Title

Frontiers in medicine

Abstract

Meningitis caused by species is a rare complication of neurosurgical procedures, although it is associated with high morbidity and mortality. Carbapenem-resistant is particularly difficult to treat, considering the limited selection and tolerability of effective antimicrobials. Sulbactam-durlobactam was approved by the FDA in 2023 for treatment of hospital-acquired and ventilator-associated pneumonia due to susceptible strains of , including carbapenem-resistant . Here, we present a case of carbapenem-resistant neurosurgical infection and meningitis successfully treated with sulbactam-durlobactam combination therapy.

ISSN

2296-858X

First Page

1381123

Recommended Citation

Snowdin, Jacob W.; Mercuro, Nicholas J.; Madaio, Michael P.; and Rawlings, Stephen A., "Case report: Successful treatment of OXA-23 neurosurgical infection and meningitis with sulbactam-durlobactam combination therapy" (2024). MaineHealth Maine Medical Center. 3697.
https://knowledgeconnection.mainehealth.org/mmc/3697